tradingkey.logo

BRIEF-Hutchmed Says NDA Acceptance In China With Priority Review Status For Orpathys And Tagrisso Combination

ReutersJan 2, 2025 12:01 AM

- HUTCHMED (China) Ltd 0013.HK:

  • HUTCHMED ANNOUNCES NDA ACCEPTANCE IN CHINA WITH PRIORITY REVIEW STATUS FOR ORPATHYS® AND TAGRISSO® COMBINATION IN LUNG CANCER PATIENTS WITH MET AMPLIFICATION AFTER PROGRESSION ON FIRST-LINE EGFR INHIBITOR THERAPY

  • HUTCHMED (CHINA) LTD - THIS ACCEPTANCE ALSO TRIGGERS A MILESTONE PAYMENT FROM ASTRAZENECA

Source text: ID:nGNX1YMGnt

Further company coverage: 0013.HK

((Reuters.Briefs@thomsonreuters.com;;))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI